Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay (TM-B1)

Blood samples from a total of 200 women in two cohorts will be collected and analyzed by TM-B1 assay, which is based on TBIA (Total Biochemical Infrared Analysis) to confirm the presence of cancer. These two cohorts will yield 75 healthy women with no pathological findings, 75 women diagnosed as having benign breast tumor and 50 women diagnosed as having breast cancer.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer
• Intervention / Treatment: Diagnostic test: Screening Population; Diagnostic test: Breast Cancer Population

Detailed Description

Prospective, two arms, observational, blinded, cohort study enrolling 200 women which intended to validate the cut-off points between women with malignant tumors, benign tumors, and women without tumors (controls) and to validate the sensitivity and specificity of TM-B1 for the detection of an invasive breast tumor.

Two cohorts will be tested with TM-B1. The cohorts will differ in the percentage of women that are expected to yield a positive finding for breast cancer. Any finding in TM-B1 will not influence medical standards of care.

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

• Study Contact: Name: Udi Zelig, Ph.D.; Phone Number: 972-55-661-6945; Email: udi@todosmedical.com
• Study Contact Backup: Name: Meir S Silver, Ph.D.; Phone Number: 972-54-633-5855; Email: meir.s@todosmedical.com

Study Locations

• Israel
  • Rehovot, Israel, 76100
    • Recruiting
    • Kaplan Medical Center
    • Contact: Tanir Alweis, M.D.; Phone Number: 972-50-787-4268; Email: taniral@clalit.org.il
    • Principal Investigator: Tanir Alweis, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Cohort 1: Screening Population - Women presenting for routine XRM and / or breast US.

Cohort 2: Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.

Description

Inclusion Criteria:

Screening Population:

• Subject signed the informed consent.
• Subject is aged 25 years and older.
• Subject is presenting for routine screening or diagnostic XRM and / or breast US.

Breast Cancer Population

• Subject signed the informed consent form.
• Subject is aged 25 years and older.
• Subject was diagnosed with a malignant breast tumor, and has not yet started treatment.

Exclusion Criteria:

All Subjects:

• Subject has been diagnosed with any type of malignancy apart from breast cancer.
• Subject has been previously treated for breast cancer.
• Subject underwent any surgery within the previous year (apart from benign nevus removal).
• Subject was treated for benign tumor within the previous year (e.g. polyps or cysts).
• Subject has an active infection or inflammation from any type of infection (bacterial or viral) as determined clinically at screening.
• Subject is currently taking medications related directly to, or that can affect, the immune system such as steroids.
• Subject has any type of active autoimmune disease such as lupus or rheumatoid arthritis.
• Diagnostic drugs (e.g. contrast materials) were injected or given orally to subject within the last 7 days prior to sample collection for TM-B1 analysis.
• Subject has been taking any investigational drug which influence her health status within 30 days prior to sample collection for TM-B1 analysis.
• Subject is not feeling well at the time of blood collection for TM-B1 analysis due to suspected bacterial or viral infection or subject has symptoms such as high fever, diarrhea, headache, vomiting, dizziness etc.
• Subject is pregnant, lactating, or undergoing fertility treatment.
• Subject has participated in this study, in another cohort, and the TM-B1 test was performed.

Breast Cancer Population only:

• The subject's tumor has been surgically removed before sample collection for TM-B1 analysis.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Screening Population; Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US. Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded.	Diagnostic test: Screening Population; Blood samples taken from screening population
Breast Cancer Population; Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.	Diagnostic test: Breast Cancer Population; Blood samples taken from Breast Cancer population

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
This study is intended to evaluate the sensitivity and specificity of the TM-B1 test compared to the Gold Standard diagnostic methods and clinical evaluations based on Digital X-Ray Mammography (XRM), and / or ultrasound, and / or MRI and / or pathology.	the subject's blood (Groups 1 and 2)will be tested for the presence of breast cancer	Timepoint 1, day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
For asymptomatic women who have dense breast tissue (parenchymal density > 50% on XRM), evaluate the performance, in terms of sensitivity and specificity, of the TM-B1 test and XRM together as a breast cancer screening procedure compared to the XRM alone	The subject's blood (Groups 1 and 2) will be tested for the presence of breast cancer	Timepoint one, day 1

Collaborators and Investigators

• Sponsor: Todos Medical, Ltd.
• Investigators: Principal Investigator: Tanir N Alweis, M.D., Kaplan Medical Center,Pasternak St., POB 1, Rehovot 76100, Israel

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2018
• Primary Completion (Anticipated): May 1, 2019
• Study Completion (Anticipated): July 1, 2019

Study Registration Dates

• First Submitted: November 12, 2017
• First Submitted That Met QC Criteria: November 12, 2017
• First Posted (Actual): November 17, 2017

Study Record Updates

• Last Update Posted (Actual): August 22, 2018
• Last Update Submitted That Met QC Criteria: August 20, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: IL-TM-B1-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No